Importance: Strabismus is common, affecting 2% to 4% of children, but how children and their families are affected in everyday life is poorly understood. Objective: To evaluate the association of strabismus with functional vision and eye-related quality of life in children and their families using the Pediatric Eye Questionnaire (PedEyeQ). Design, Setting, and Participants: This cross-sectional study was conducted between December 2017 and October 2019 and included 91 children with strabismus and 166 visually normal controls across 3 age groups (0-4, 5-11, and 12-17 years) who were enrolled at Mayo Clinic, Rochester, Minnesota, and Retina Foundation of the Southwest, Dallas, Texas. Exposures: Children completed the child PedEyeQ (5 to 11- and 12 to 17-year versions: functional vision, bothered by eyes/vision, social, and frustration/worry domains); parents completed the proxy (0 to 4-, 5 to 11-, and 12 to 17-year versions: functional vision, bothered by eyes/vision, social, frustration/worry, and eye care domains) and the parent PedEyeQ (impact on parent and family, worry about child's eye condition, worry about child's self-perception and interactions, and worry about child's functional vision domains). Rasch-calibrated PedEyeQ scores were calculated for each domain and converted to 0 (worst) to 100. Main Outcomes and Measures: PedEyeQ domain scores. Results: Of 91 participants with strabismus, 41 (45.1%) were girls, 74 (81.3%) were white, 4 (4.4%) were Asian, 5 (5.5%) were more than 1 race, 5 (5.5%) were African American, and 2 (2.2%) were American Indian/Alaska Native. Child PedEyeQ domain scores were lower with strabismus vs visually normal controls among children ages 5 to 11 years and the greatest mean (SD) difference was in functional vision (12 [14] points; 95% CI, 6-18; P = .001), and among children ages 12 to 17 years, the greatest mean (SD) difference was in frustration/worry (27 [13] points; 95% CI, 18-36; P < .001). Proxy PedEyeQ domain scores were also lower with strabismus. The greatest difference among children ages 0 to 4 years was in functional vision (13 [9] points; 95% CI, 9-16; P < .001), among children ages 5 to 11 years was in functional vision (26 [10] points; 95% CI, 22-30; P < .001); and among children ages 12 to 17 years was in functional vision (21 [12] points; 95% CI, 12-30; P < .001), social (21 [13] points; 95% CI, 12-30; P < .001), and frustration/worry (21 [13] points; 95% CI, 12-30; P < .001). Parent PedEyeQ domain scores were lower with strabismus; the greatest difference was in worry about child's eye condition (38 [14] points; 95% CI, 34-42; P < .001). Conclusions and Relevance: Strabismus is associated with reduced functional vision and eye-related quality of life in children. Parents of children with strabismus also experience a reduced quality of life. These findings advance our understanding of how strabismus affects children and their families and should be considered when defining patient management goals.
Importance: Strabismus is common, affecting 2% to 4% of children, but how children and their families are affected in everyday life is poorly understood. Objective: To evaluate the association of strabismus with functional vision and eye-related quality of life in children and their families using the Pediatric Eye Questionnaire (PedEyeQ). Design, Setting, and Participants: This cross-sectional study was conducted between December 2017 and October 2019 and included 91 children with strabismus and 166 visually normal controls across 3 age groups (0-4, 5-11, and 12-17 years) who were enrolled at Mayo Clinic, Rochester, Minnesota, and Retina Foundation of the Southwest, Dallas, Texas. Exposures: Children completed the child PedEyeQ (5 to 11- and 12 to 17-year versions: functional vision, bothered by eyes/vision, social, and frustration/worry domains); parents completed the proxy (0 to 4-, 5 to 11-, and 12 to 17-year versions: functional vision, bothered by eyes/vision, social, frustration/worry, and eye care domains) and the parent PedEyeQ (impact on parent and family, worry about child's eye condition, worry about child's self-perception and interactions, and worry about child's functional vision domains). Rasch-calibrated PedEyeQ scores were calculated for each domain and converted to 0 (worst) to 100. Main Outcomes and Measures: PedEyeQ domain scores. Results: Of 91 participants with strabismus, 41 (45.1%) were girls, 74 (81.3%) were white, 4 (4.4%) were Asian, 5 (5.5%) were more than 1 race, 5 (5.5%) were African American, and 2 (2.2%) were American Indian/Alaska Native. Child PedEyeQ domain scores were lower with strabismus vs visually normal controls among children ages 5 to 11 years and the greatest mean (SD) difference was in functional vision (12 [14] points; 95% CI, 6-18; P = .001), and among children ages 12 to 17 years, the greatest mean (SD) difference was in frustration/worry (27 [13] points; 95% CI, 18-36; P < .001). Proxy PedEyeQ domain scores were also lower with strabismus. The greatest difference among children ages 0 to 4 years was in functional vision (13 [9] points; 95% CI, 9-16; P < .001), among children ages 5 to 11 years was in functional vision (26 [10] points; 95% CI, 22-30; P < .001); and among children ages 12 to 17 years was in functional vision (21 [12] points; 95% CI, 12-30; P < .001), social (21 [13] points; 95% CI, 12-30; P < .001), and frustration/worry (21 [13] points; 95% CI, 12-30; P < .001). Parent PedEyeQ domain scores were lower with strabismus; the greatest difference was in worry about child's eye condition (38 [14] points; 95% CI, 34-42; P < .001). Conclusions and Relevance: Strabismus is associated with reduced functional vision and eye-related quality of life in children. Parents of children with strabismus also experience a reduced quality of life. These findings advance our understanding of how strabismus affects children and their families and should be considered when defining patient management goals.
Authors: James R Drover; Joost Felius; Christina S Cheng; Sarah E Morale; Lauren Wyatt; Eileen E Birch Journal: J AAPOS Date: 2007-12-26 Impact factor: 1.220
Authors: Ge Wen; Roberta McKean-Cowdin; Rohit Varma; Kristina Tarczy-Hornoch; Susan A Cotter; Mark Borchert; Stanley Azen Journal: Ophthalmology Date: 2010-09-29 Impact factor: 12.079
Authors: Ying Pan; Kristina Tarczy-Hornoch; Susan A Cotter; Ge Wen; Mark S Borchert; Stanley P Azen; Rohit Varma Journal: Optom Vis Sci Date: 2009-06 Impact factor: 1.973
Authors: Sarah R Hatt; David A Leske; Yolanda S Castañeda; Suzanne M Wernimont; Laura Liebermann; Christina S Cheng-Patel; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2018-09-21 Impact factor: 1.220
Authors: Laura Liebermann; David A Leske; Yolanda S Castañeda; Sarah R Hatt; Suzanne M Wernimont; Christina S Cheng; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2016-07-02 Impact factor: 1.220
Authors: Alexander K Schuster; Heike M Elflein; Roman Pokora; Martin Schlaud; Franz Baumgarten; Michael S Urschitz Journal: Health Qual Life Outcomes Date: 2019-05-07 Impact factor: 3.186
Authors: David A Leske; Sarah R Hatt; Suzanne M Wernimont; Yolanda S Castañeda; Christina S Cheng-Patel; Laura Liebermann; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2021-02-16 Impact factor: 1.220
Authors: Sarah R Hatt; David A Leske; Suzanne M Wernimont; Erick D Bothun; Eileen E Birch; Jonathan M Holmes Journal: J AAPOS Date: 2021-08-20 Impact factor: 1.325
Authors: Sarah R Hatt; David A Leske; Suzanne M Wernimont; Erick D Bothun; Eileen E Birch; Jonathan M Holmes Journal: J Binocul Vis Ocul Motil Date: 2022-02-01
Authors: David A Leske; Sarah R Hatt; Suzanne M Wernimont; Yolanda S Castañeda; Christina S Cheng-Patel; Laura Liebermann; Eileen E Birch; Jonathan M Holmes Journal: Am J Ophthalmol Date: 2020-10-28 Impact factor: 5.258
Authors: Eileen E Birch; Yolanda S Castañeda; Christina S Cheng-Patel; Sarah E Morale; Krista R Kelly; Reed M Jost; Lindsey A Hudgins; David A Leske; Jonathan M Holmes Journal: Invest Ophthalmol Vis Sci Date: 2020-09-01 Impact factor: 4.799
Authors: Mary C Whitman; Silvio Alessandro Di Gioia; Wai-Man Chan; Alon Gelber; Brandon M Pratt; Jessica L Bell; Thomas E Collins; James A Knowles; Christopher Armoskus; Michele Pato; Carlos Pato; Sherin Shaaban; Sandra Staffieri; Sarah MacKinnon; Gail D E Maconachie; James E Elder; Elias I Traboulsi; Irene Gottlob; David A Mackey; David G Hunter; Elizabeth C Engle Journal: Invest Ophthalmol Vis Sci Date: 2020-08-03 Impact factor: 4.799